Unravelling the oncogenic potential and prognostic significance of MAPT in breast cancer: An In-Silico inhibition of MAPT by paclitaxel

Breast cancer is the second top mortality of women globally. A major difficulty in therapeutic therapy is the disease's heterogeneity. However, modern discoveries in molecular biology and immunology have made it possible to create highly focused medicines for a variety of breast tumor subtypes. The fundamental aim of targeted treatments is to inhibit the growth of tumors by blocking the activity of a particular target or molecule. Morphological alterations in neuronal-glial cells have been linked to breast cancer (BC) on several occasions. However, the processes by which these neuronal proteins are regulated remain unclear despite their association with cancer. Analysis of the expression of genes in tissues of human BC has recognized microtubule-binding protein Tau to be a newly identified marker of response to paclitaxel and a modulator of paclitaxel sensitivity. In terms of taxane resistance pathways, those involving MAPs (microtubule-associated proteins) such as Tau are crucial. Reduced concentration of the Tau protein makes the microtubules of the mitochondrion and the cytoskeleton more vulnerable to the effects of the drug paclitaxel, which can disrupt mitosis and interfere with cell signalling. Clinical and preclinical data from the past several years support the hypothesis that ER induces the gene MAP-Tau and the resulting expression of the Tau protein influences the susceptibility of malignant cells to taxanes. This study illustrates the expression pattern and prognostic significance of MAPT (Microtubule-Associated Proteins Tau) in BC and targeting MAPT using Paclitaxel drug. The present study employed both In Silico and In Vitro methodologies to evaluate the expression profile, prognostic, and therapeutic value of the MAPT gene in BC and discover the interactions of MAPT in breast cancer pathogenesis. The In-Silico and In-Vitro studies have also revealed that patients with BC will have much better therapeutic responses when MAPT is inhibited in addition to normal therapies because overexpression of MAPT promotes tumor formation. Overall, our research indicates that MAPT is associated with tumor growth in BC cells and its dysregulation has been implicated in breast cancer pathogenesis. • The dysregulated expression pattern of Tau has been associated with worse prognosis and therefore acts as a potential prognostic biomarker in breast cancer. • The In-Silico inhibition of Tau with Paclitaxel drug proves to be a potent anticancer approach in breast cancer. • Utilising a combination approach that includes targeting MAPT alongside other therapeutic medications holds great promise for enhancing treatment responses among breast cancer patients and mitigating the emergence of chemotherapy resistance.